Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. has initiated a Phase 3 clinical study titled ‘MagnetisMM-32’ to evaluate the effectiveness of elranatamab in patients with relapsed or refractory multiple myeloma, a type of cancer that has returned after prior treatments. The study aims to compare elranatamab monotherapy against established combination therapies, providing insights into its safety and efficacy.
The intervention being tested is elranatamab, an experimental drug administered subcutaneously, designed to treat multiple myeloma. It is being compared to combination therapies involving drugs like elotuzumab, pomalidomide, and dexamethasone, among others.
The study is interventional, with participants randomly assigned to receive either elranatamab or a combination therapy. It follows a parallel intervention model with no masking, focusing primarily on treatment outcomes.
The study began on February 8, 2024, with the latest update submitted on July 28, 2025. These dates are crucial as they mark the study’s progress and timeline for potential results.
This update could influence Pfizer’s stock performance positively, as successful results may enhance investor confidence. However, competition remains stiff in the oncology sector, with numerous companies vying for market share in multiple myeloma treatments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.